ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

At ORIC, our mission is to discover, develop and commercialize targeted therapies that provide innovative and meaningful treatment options to patients. We strive to build an organization that values transparency, excellence, and accountability and is dedicated to collaboration and delivering on our commitments.

Our vision is to become a leader in the development of highly targeted therapies for the treatment of cancer and serious medical diseases.

ORIC has been awarded a number of awards, including the prestigious SF Bay Area Biotech of the Year Award, the National Cancer Institute’s ‘Most Innovative Predictive Cancer Clinical Trial Awards’ and the ‘Recognition of Excellence’ award from the San Francisco Business Times.